GlaxoSmithKline is assessing its global research and development facilities, which could lead to some of its less established centres closing.
It has more than half a dozen facilities in the UK and the US.
It wants to concentrate research around
Thank you for reading EG
Want to read more? Enjoy a story a week for FREE for one month.
